Allarity Therapeutics, Inc.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash | $14.7M-24.8% | $19.5M+11666.9% | $166K-91.8% | $2.0M-89.6% | $19.6M |
| Receivables from ATM sales | $0-100.0% | $1.4M | $0 | — | — |
| Other current assets | $265K+130.4% | $115K-45.0% | $209K-86.6% | $1.6M+149.4% | $625K |
| Prepaid expenses | $2.1M+316.2% | $507K-35.1% | $781K+32.1% | $591K+1541.7% | $36K |
| Tax credit receivable | $866K+12.5% | $770K-5.5% | $815K+3.3% | $789K-5.8% | $838K |
| Total current assets | $17.9M-19.8% | $22.3M+1033.5% | $2.0M-60.3% | $5.0M-76.8% | $21.4M |
| Property, plant and equipment, net | $330K+6.8% | $309K+1445.0% | $20K-4.8% | $21K+162.5% | $8K |
| Total assets | $18.3M-19.4% | $22.6M+90.9% | $11.9M-18.4% | $14.5M-70.7% | $49.6M |
| Accounts payable | $4.3M+2.4% | $4.2M-50.3% | $8.4M+34.6% | $6.3M+795.6% | $698K |
| Accrued expenses and other current liabilities | $2.7M-49.0% | $5.2M+299.7% | $1.3M-31.3% | $1.9M-77.8% | $8.6M |
| Warrant derivative liability | $0-100.0% | $1K-100.0% | $3.1M+724.3% | $374K-96.7% | $11.3M |
| Income taxes payable | $81K+9.5% | $74K+25.4% | $59K+43.9% | $41K-31.7% | $60K |
| Convertible promissory note and accrued interest | $1.4M+3.7% | $1.4M+3.8% | $1.3M | — | — |
| Total current liabilities | $8.4M-22.2% | $10.8M-23.5% | $14.2M+26.2% | $11.2M-45.8% | $20.7M |
| Total liabilities | $8.4M-22.2% | $10.8M-25.8% | $14.6M+15.5% | $12.7M-59.0% | $30.8M |
| Common stock, $0.0001 par value (250,000,000 shares authorized); 19,030,619 and 7,302,797 shares issued and 16,080,980 and 7,302,797 outstanding at December 31, 2025, and December 31, 2024, respectively | $3K+200.0% | $1K | $0 | — | $1K |
| Additional paid-in capital | $144.2M+10.0% | $131.1M+45.1% | $90.4M+8.7% | $83.2M-2.4% | $85.2M |
| Accumulated other comprehensive loss | -$1.0M-188.4% | -$354K+13.9% | -$411K+43.0% | -$721K-20.2% | -$600K |
| Accumulated deficit | -$130.2M-9.4% | -$119.0M-26.0% | -$94.5M-14.4% | -$82.5M-24.2% | -$66.5M |
| Treasury stock, at cost; 2,949,639 shares | -$3.2M | $0 | — | — | — |
| Total stockholders’ equity | $9.8M-16.8% | $11.8M+529.3% | -$2.8M-2334.5% | -$113K-100.6% | $18.2M |
| Total liabilities and stockholders’ equity | $18.3M-19.4% | $22.6M+90.9% | $11.9M-18.4% | $14.5M-70.7% | $49.6M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
No Form 4 transactions on record.
Informational purposes only, not investment advice.